Amneal Pharmaceuticals has announced the US launch of bimatoprost ophthalmic solution 0.01%, a generic equivalent to Allergan/AbbVie’s LUMIGAN, expanding options for clinicians managing glaucoma and ocular hypertension.
The prostaglandin analogue, available in 2.5 mL, 5 mL, and 7.5 mL bottles, is indicated for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. With US annual sales of the reference product reaching approximately $719 million (IQVIA, February 2026), the entry of a generic alternative is expected to improve affordability and access for patients.
Amneal positioned the launch as part of its broader strategy to grow its Affordable Medicines segment, with leadership highlighting the increasing burden of glaucoma and the need for accessible long-term therapies.
“As glaucoma prevalence continues to rise, particularly among the aging population, expanding access to effective treatments like bimatoprost is critical,” said Senior Vice President, Dr. Srinivas Kone. “This launch builds on our strong cadence of complex product introductions and represents an important growth driver for our Affordable Medicines segment.”
For ophthalmologists, the arrival of another generic bimatoprost formulation may support treatment adherence by reducing cost barriers, especially in chronic IOP management where sustained therapy is essential to prevent progression.
The safety profile is consistent with the branded product, with conjunctival hyperemia reported as the most common adverse event.
The launch reflects ongoing competition within the prostaglandin analogue class, where generics continue to play a central role in first-line glaucoma therapy. As pricing pressures and access considerations remain key in clinical decision-making, additional generic entries could further shift prescribing patterns in favor of cost-effective options.
Amneal’s ophthalmic portfolio expansion underscores continued industry focus on high-volume, chronic eye diseases – where balancing efficacy, tolerability, and affordability remains critical in real-world care.
Source: Amneal Pharmaceuticals.
